Ziprasidone
Small molecule
Evidence outlook
Approved: Schizophrenia, Bipolar Disorder
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT00159770 NCT00159770 · Schizophrenia, Schizoaffective Disorder, Psychotic Disorders This 12-week, open-label, multicentre trial randomized 293 patients with chronic schizophrenia to ziprasidone (n=147) or to a comparator group of olanzapine, risperidone or quetiapine chosen by the investigator (n=146). The primary endpoint was total PANSS score, tested for non-inferiority with a margin of 7 points to the disadvantage of ziprasidone. Ziprasidone was non-inferior to the comparator group on total PANSS and on all subscores (P<0.0001), so the primary endpoint was met. The figures come from the peer-reviewed paper (Lublin et al., World J Biol Psychiatry 2009), whose abstract does not give a confidence interval. Registry: NCT00159770 | 3 | PANSS (The Positive And Negative Syndrome Scale) in a 12 week period | Ziprasidone non-inferior to the olanzapine/risperidone/quetiapine group on total PANSS (margin 7 units; P<0.0001). | Partial signal | link ↗ |
View 1 more trial
HDZ NCT00403546 · Schizophrenia This randomized, double-blind trial compared high-dose ziprasidone (320 mg/day) with continued standard-dose ziprasidone (160 mg/day plus placebo capsules) for 8 weeks in patients whose schizophrenia remained symptomatic on the standard dose. Of 131 people who entered the open-label phase, 75 were randomized (38 and 37) and 42 completed. The control arm received active ziprasidone, so the study is a dose comparison. The change in PANSS total score did not differ between the groups at Week 8 (-8.62 vs -5.48, p=0.642) or at any earlier visit, and no other registered primary measure favoured the high dose. The extrapyramidal symptom score was worse with the high dose at Week 2 (p=0.033). The primary efficacy comparison was missed, and the small randomized sample limits the result. The figures come from the ClinicalTrials.gov posted results. Registry: NCT00403546 | 3 | Number of Events Recorded Based on Ziprasidone Side Effects Checklist During Randomized Trial (From Baseline up to Week 8); Change From Baseline in Simpson Angus Scale for Extrapyramidal Symptoms (SAS) (Baseline, Week 2, Week 4, Week 6, Week 8); Change From Baseline in the Barnes Akathisia Scale (BAS) (Baseline, Week 2, Week 4, Week 6, Week 8); Number of Participants With High and Low Levels in Serum Prolactin Concentration (Baseline, Week 8); Vital Signs: Systolic and Diastolic Blood Pressure Levels (Baseline, Week 1, Week 2, Week 4, Week 6, Week 8); Electrocardiogram (EKG): Number of Participants With an Increase From Baseline to Corrected QT (QTc) Interval >/= 500 Milliseconds (Msec) (6 hours after dosing of Weeks 1, 2 and 8); Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score (Baseline, Week 2, Week 4, Week 6, Week 8); Percentage of Participants With Response (Baseline, Week 2, Week 4, Week 6, Week 8); Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Score (Baseline, Week 2, Week 4, Week 6, Week 8); Number of Treatment-emergent Adverse Events During Randomized Trial (From Baseline up to Week 8) 2011-05 | Change from baseline in PANSS total score at Week 8, high-dose ziprasidone (320 mg/day) vs standard dose (160 mg/day plus placebo capsules): -8.62 vs -5.48, mixed-model difference -1.37 (95% CI -7.20 to 4.45), p=0.642. No registered primary favoured the high dose; the Simpson-Angus extrapyramidal score was worse on the high dose at Week 2 (difference 1.02, 95% CI 0.08 to 1.95, p=0.033). | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (32)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (47)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (10)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (6)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (1)
What this study did
Phase 1 (1)
What this study did
Phase 4 (3)
What this study did
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Appears in other studies (3)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 2 (2)
What this study did
What this study did
Phase 4 (1)
What this study did
Competitive landscape
Other Dopamine D2 and serotonin 5-HT2A receptors (antagonist) drugs
Asenapine, Clozapine, Iloperidone (Fanapt), Lurasidone, Milsaperidone (VHX-896) and 17 more. Compare all 23 Dopamine D2 and serotonin 5-HT2A receptors (antagonist) drugs
This mechanism is crowded: 24 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Bipolar Disorder: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Ziprasidone: this drug | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Aripiprazole (Abilify Maintena) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D2/D3 and serotonin 5-HT1A receptor, Dopamine D2 receptor (partial agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Aripiprazole (Abilify) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Asenapine | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Cariprazine (Vraylar) | Approved | Small molecule | Dopamine D3/D2 receptor (partial agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Divalproex Sodium (Depakote ER) | Approved | Small molecule | GABAergic neurotransmission | not yet graded | No reviewed efficacy summary in this indication | |
| Divalproex Sodium (Depakote) | Approved | Small molecule | GABAergic neurotransmission | Partial signal | Featured results are non-efficacy only in this race | |
| Iloperidone (Fanapt) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Lamotrigine | Approved | Small molecule | Voltage-gated sodium channel | not yet graded | No reviewed efficacy summary in this indication | |
| Milsaperidone (VHX-896) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | Weak signal | No reviewed efficacy summary in this indication | |
| Olanzapine (Zyprexa) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Olanzapine / Samidorphan (Lybalvi) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist); mu-opioid receptor (antagonist) | Reliable signal | No reviewed efficacy summary in this indication | |
| Quetiapine (Seroquel XR) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Quetiapine (Seroquel) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Risperidone (Risperdal Consta) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Risperidone (Risperdal) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Risperidone (Rykindo) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Risperidone (Uzedy) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Dexmedetomidine (Igalmi) | Phase 3 | Small molecule | Alpha-2 adrenergic receptor (agonist) | Reliable signal | No reviewed efficacy summary in this indication | |
| Loxapine (Adasuve) | Phase 3 | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | Partial signal | No reviewed efficacy summary in this indication | |
| Xanomeline / Trospium Chloride (Cobenfy) | Phase 3 | Small molecule | Muscarinic M1/M4 receptor (agonist/antagonist combination) | not yet graded | No reviewed efficacy summary in this indication | |
| ALTO-100 | Phase 2 | Small molecule | First-in-class oral small molecule neural plasticity enhancer | not yet graded | No reviewed efficacy summary in this indication | |
| Brenipatide | Phase 2 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Elunetirom | Phase 2 | Small molecule | Thyroid hormone receptor-beta | not yet graded | No reviewed efficacy summary in this indication | |
| Icalcaprant | Phase 2 | Small molecule | Kappa-opioid receptor (inhibitor) | not yet graded | No reviewed efficacy summary in this indication | |
| Lithium Salicylate / L-Proline (AL001) | Phase 1/2 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-1042 | Phase 1(overall) | Small molecule | Muscarinic M4 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Aripiprazole (Abilify MyCite) | Discontinued | Combination | Dopamine D2 and serotonin 5-HT1A receptors (partial agonist); serotonin 5-HT2A receptor (antagonist) | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
16 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Ziprasidone to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.